Clinical trials: Steatosis
MASLD, Fatty Liver
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver.
- Trial name
- NCT07646197
- Testing
- Peanut consumption
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Henry Ford Health System
Non-alcoholic Steatohepatitis
Clinical Effects of New Approach on Patients With Non-alcoholic Steatohepatitis
This study aims to evaluate and compare the protective outcomes of using Rosuvastatin, Vitamin E, and N-acetyl cysteine in Egyptian patients with NASH.
- Trial name
- NCT06105060
- Testing
- Rosuvastatin 20mg
- Where
- Egypt
- Volunteers
- 175 people
- Sponsor
- Beni-Suef University
Non Alcoholic Steatohepatitis
The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease
To study the effects of Hesperidin supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI)…
- Trial name
- NCT03377140
- Testing
- Hesperidin, control
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
DIABETES MELLITUS
The Effect of Vitamin D Supplementation in Type 2 Diabetes
In many observational studies, vitamin D deficiency is related to glucose intolerance and diabetes. But there little randomized, controlled interventional studies that evaluate the effect of vitamin D in type 2 diabetes.
- Trial name
- VD2000 (NCT01854463)
- Testing
- Vitamin D3
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Metabolic-associated Fatty Liver Disease
Efficacy and Safety of Rifaximin in Treating MAFLD
Study Objective: to evaluate the efficacy and safety of rifaximin in the treatment of metabolic-associated fatty liver disease (MAFLD), and investigate the underlying mechanisms by which rifaximin influence MAFLD progression.
- Trial name
- NCT07185932
- Testing
- Rifaximin (Xifaxan)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Changzheng Hospital
Non-alcoholic Steatohepatitis
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
Novo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT05766709
- Testing
- NNC0194-0499, Semaglutide, NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- Where
- Canada
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
NASH - Nonalcoholic Steatohepatitis
Phase 2a Study of HPG1860 in Subjects With NASH
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel group, multiple arm, multicenter study of 3 different doses of HPG1860 versus placebo in subjects with biopsy-confirmed or phenotypic NASH.
- Trial name
- RISE (NCT05338034)
- Testing
- HPG1860
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Hepagene (Shanghai) Co., Ltd.
NAFLD, Overweight and Obesity
The Acute Effects of Eucaloric and Hypocaloric Carbohydrate Restriction on Liver Fat Content and Metabolism in Obese Individuals
The primary aim of this study is to investigate the acute changes in liver fat content in response to a fixed carbohydrate restriction (i.e.
- Conditions
- NAFLD, Overweight and Obesity, Metabolic Syndrome, Diabetes
- Trial name
- FixedCarb (NCT05643521)
- Testing
- Dietary composition of macronutrients and calories
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients)…
- Trial name
- NCT05084404
- Testing
- Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Yokohama City University
NASH - Nonalcoholic Steatohepatitis
Pentoxifylline in Treatment of Patients With Nonalcoholic Steatohepatitis
The aim of the present study is to evaluate the efficacy and safety of pentoxifylline in the treatment of non-alcoholic steatohepatitis patients.
- Trial name
- NCT05284448
- Testing
- pentoxifylline (Trental SR®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Al-Azhar University
Obesity, Non-Alcoholic Fatty Liver Disease
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity.
- Conditions
- Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
- Trial name
- ATM (NCT06571474)
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bettina Mittendorfer
Non Alcoholic Fatty Liver Disease
Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial
Now considered as a major public health challenge, non-alcoholic fatty liver disease (NAFLD) is rapidly rising as a major cause of end-stage liver disease.
- Trial name
- S@VE-LIVER (NCT07497750)
- Testing
- Fibroscan CAP/VTE, Randomization, MRI-PDFF
- Where
- 9 sites in France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease
Positive Association of US-FLI With the Severity of CAD
As a multisystem disease, metabolic dysfunction-associated fatty liver disease (MAFLD) is closely linked to the onset and progression of coronary heart disease (CHD).
- Conditions
- Coronary Artery Disease of Significant Bypass Graft, Metabolic Dysfunction-associated Fatty Liver Disease, SYNTAX Score, Ultrasonography
- Trial name
- NCT06541132
- Testing
- Observational study without human intervention
- Where
- China
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Chongqing Medical University
Liver Diseases
Pioglitazone vs Vitamin E vs Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS)
The purpose of this study is to determine if therapy with pioglitazone or vitamin E will lead to an improvement in liver histology in non-diabetic adult patients with non-alcoholic steatohepatitis (NASH).
- Trial name
- PIVENS (NCT00063622)
- Testing
- Pioglitazone, Vitamin E
- Where
- 8 sites in United States
- Volunteers
- 247 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease
Effect of Mediterranean Diet in Obese Adolescents With Nonalcoholic Fatty Liver Disease
The aim of this study was to evaluate the effects of mediterranean and low-fat diet on hepatic fat, inflammation markers and oxidative stress in adolescents with nonalcoholic fatty liver disease.
- Trial name
- NCT04845373
- Testing
- Mediterranean diet, Control diet: Low fat diet
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Gazi University
NAFLD, Accupuncture
Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver dysfunction worldwide. NAFLD may progress to nonalcoholic steatohepatitis (NASH) and in turn to cirrhosis.
- Trial name
- NCT02006329
- Testing
- acupuncture
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Ziv Hospital
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
- Trial name
- MIRNA (NCT04321031)
- Testing
- PF-06865571, PF-05221304
- Where
- 291 sites in United States, Bulgaria and 10 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Fatty Liver, Intermittent Fasting
Intermittent Fasting for NAFLD in Adults
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI<30kg/m2) is an increasingly recognized condition, sometimes described as "lean…
- Conditions
- Fatty Liver, Intermittent Fasting, Fatty Liver, Nonalcoholic, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT04899102
- Testing
- Time-Restricted, Intermittent Fasting
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Obesity, Diabetes
Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance
The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects
- Conditions
- Obesity, Diabetes, Insulin Resistance, Fatty Liver
- Trial name
- HEPFAT (NCT01038102)
- Testing
- PUFA Diet, SFA diet
- Where
- Sweden
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Growth Hormone Deficiency
Insulin Sensitivity and Substrate Metabolism Before and After Treatment in Patients With Growth Hormone Deficiency
The purpose of this study is to further characterize the treatment related changes in insulin sensitivity, substrate metabolism and intrahepatic-intramyocellular lipids in patients with growth hormone deficiency (GHD).
- Trial name
- NCT00646815
- Testing
- growth hormone (genotropin)
- Where
- 2 sites in Denmark
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.